New ultrasound method for diagnosing breast tumors
Official title: 3D Multimodal Ultrasound Imaging for Breast Cancer
Run by Mayo Clinic · NCT04692818 · Data updated 2026-11-12
This study tests a new 3D ultrasound method to see if it can better diagnose breast tumors in women compared to traditional imaging techniques.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 125 (estimated) |
| Sponsor | Mayo Clinic Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Rochester, Minnesota) |
| Status | Recruiting |
| Started | November 10, 2021 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | June 1, 2026 |
| Trial ID | NCT04692818 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adult women aged 18 and older with solid breast lesions measuring 3mm or larger.
✕Probably not a fit
Patients who are under 18 years of age, pregnant, lactating, or currently receiving cancer therapy may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This research investigates the effectiveness of a novel 3D ultrasound imaging technique for diagnosing breast masses. The study utilizes advanced ultrasound technology, including the GE Logiq E10 clinical ultrasound scanner and the Verasonics research scanner, to enhance imaging quality and accuracy. Adult women with solid breast lesions will be evaluated to determine the diagnostic capabilities of this new method compared to traditional imaging techniques.
Why it matters
Potential benefit: If successful, this study could lead to more accurate and earlier diagnosis of breast tumors, improving patient outcomes.
How similar studies have gone: Other studies have shown promising results with advanced ultrasound imaging techniques, suggesting potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult women ≥ 18 years of age. * solid breast lesion and ultrasound guided biopsy (either as part of their clinical care or through participation in other IRB-approved studies) * lesion size of 3mm or larger Exclusion Criteria: * \< 18 years of age. * Lacking capacity to consent * Pregnant or lactating * Receiving cancer therapy such as chemotherapy or radiation therapy
Where it's running
-
Mayo Clinic in Rochester
Rochester, Minnesota, United States Recruiting
Study contacts
- Principal investigator: Shigao Chen, PhD — Mayo Clinic
- Study coordinator: Bobbie Ott
- Email: Ott.Bobbie@mayo.edu
- Phone: 507-293-0922
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
HTR2 CAR T Cells Targeting HER2 in Metastatic Breast Cancer
A one-time treatment with specially modified T cells that target HER2-positive metastatic breast cancer is tested to see if it’s safe and how long the cells last, with a plan for possible dose increases.
-
Evaluating the impact of MR-guided radiation therapy on cancer treatment outcomes
This study is testing how using a special type of radiation therapy with real-time imaging can improve treatment results and quality of life for adults with cancer.
-
Registry for metastatic breast cancer in Austria
This study is collecting information from people with metastatic breast cancer in Austria to better understand the disease and how different treatments are working.
-
Proton therapy for early stage breast cancer treatment
This study is testing whether proton therapy can be a better treatment for women with early stage breast cancer by focusing on the tumor while reducing side effects compared to traditional radiation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.